Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

18Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

Background: Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenance therapy in RRMM patients. Methods: Ninety patients have been included. Ixazomib–thalidomide–dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) was scheduled for eight cycles followed by maintenance with ixazomib for one year. Results: The overall response rate was 51.1%, 23.3% achieved CR or VGPR and 10% MR resulting in a clinical benefit rate of 61.1%. In patients completing ≥2 cycles, the rates were 60.5%, 27.6% and 68.4%, respectively. Median progression-free survival (PFS) was 8.5 months in all, and 9.4 months in those completing ≥2 cycles. Response rates, PFS and overall survival (OS) were similar in patients with and without t(4;14) and/or del(17p), but PFS and OS was significantly shorter in patients with gain of 1q21. Multivariate regression analysis revealed gain of 1q21 as the most important factor associated with OS. Ixazomib maintenance resulted in an upgrade in the depth of response in 12.4% of patients. Grade 3/4 toxicities were relatively rare. Conclusions: Ixazomib–thalidomide–dexamethasone followed by ixazomib maintenance therapy is active and well tolerated in patients with RRMM. Trial registration number: NCT02410694.

References Powered by Scopus

Nonparametric Estimation from Incomplete Observations

50789Citations
N/AReaders
Get full text

Daratumumab, bortezomib, and dexamethasone for multiple myeloma

1248Citations
N/AReaders
Get full text

Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma

906Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Design and discovery of boronic acid drugs

140Citations
N/AReaders
Get full text

Targeting the ubiquitin-proteasome system for cancer therapeutics by small-molecule inhibitors

51Citations
N/AReaders
Get full text

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

16Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ludwig, H., Poenisch, W., Knop, S., Egle, A., Schreder, M., Lechner, D., … Zojer, N. (2019). Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. British Journal of Cancer, 121(9), 751–757. https://doi.org/10.1038/s41416-019-0581-8

Readers over time

‘19‘20‘21‘22‘23‘240481216

Readers' Seniority

Tooltip

Professor / Associate Prof. 4

31%

PhD / Post grad / Masters / Doc 4

31%

Researcher 4

31%

Lecturer / Post doc 1

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 12

71%

Biochemistry, Genetics and Molecular Bi... 3

18%

Materials Science 1

6%

Chemistry 1

6%

Save time finding and organizing research with Mendeley

Sign up for free
0